Role of mTOR in solid tumor systems: A therapeutical target against primary tumor growth, metastases, and angiogenesis

Cancer and Metastasis Reviews

Volumn 26, Issue 3-4, 2007, Pages 611-621

  Seeliger, Hendrik ^a   Guba, Markus ^a   Kleespies, Axel ^a   Jauch, Karl Walter ^a   Bruns, Christiane J ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Angiogenesis; mTOR; Rapamycin; Solid tumors

Indexed keywords

ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEFITINIB; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VATALANIB;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ASTHENIA; BIPOLAR DISORDER; BREAST CANCER; CELL INVASION; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; ESOPHAGUS CANCER; GLIOBLASTOMA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TUMOR CELL; TUMOR GROWTH;

ANIMALS; CELL PROLIFERATION; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 36148962868     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-007-9077-8     Document Type: Review

References (108)

1. Easton, J. B., & Houghton, P. J. (2006). mTOR and cancer therapy. Oncogene, 25, 6436-6446.
2. Heitman, J., Movva, N. R., & Hall, M. N. (1991). Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science, 253, 905-909.
3. Schmelzle, T., & Hall, M. N. (2000). TOR, a central controller of cell growth. Cell, 103, 253-262.
4. Del Bufalo, D., Ciuffreda, L., Trisciuoglio, D., Desideri, M., Cognetti, F., Zupi, G., et al. (2006). Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Research, 66, 5549-554.
5. Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., et al. (2002). Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nature Medicine, 8, 128-135.
6. Shinohara, E. T., Cao, C., Niermann, K., Mu, Y., Zeng, F., Hallahan, D. E., et al. (2005). Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene, 24, 5414-5422.
7. Bjornsti, M. A., & Houghton, P. J. (2004). The TOR pathway: a target for cancer therapy. Nature Reviews, Cancer, 4, 335-348.
8. Wullschleger, S., Loewith, R., & Hall, M. N. (2006). TOR signaling in growth and metabolism. Cell, 124, 471-484.
9. Fingar, D. C., Salama, S., Tsou, C., Harlow, E., & Blenis, J. (2002). Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes & Development, 16, 1472-1487.
10. Murakami, M., Ichisaka, T., Maeda, M., Oshiro, N., Hara, K., Edenhofer, F., et al. (2004). mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Molecular and Cellular Biology, 24, 6710-6718.
11. Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., et al. (2001). Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proceedings of the National Academy of Sciences of the United States of America, 98, 10314-10319.
12. Wullschleger, S., Loewith, R., Oppliger, W., & Hall, M. N. (2005). Molecular organization of target of rapamycin complex 2. Journal of Biological Chemistry, 280, 30697-30704.
13. Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Ruegg, M. A., Hall, A., et al. (2004). Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nature Cell Biology, 6, 1122-1128.
14. Sarbassov, D. D., Ali, S. M., Kim, D. H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., et al. (2004). Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Current Biology, 14. 1296-1302.
15. Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 307, 1098-1101.
16. Zeng, Z., Sarbassov dos, D., Samudio, I. J., Yee, K. W., Munsell, M. F., Ellen Jackson, C., et al. (2007). Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood, 109, 3509-3512.
17. Inoki, K., Li, Y., Xu, T., & Guan, K. L. (2003). Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes & Development, 17, 1829-1834.
18. Long, X., Lin, Y., Ortiz-Vega, S., Busch, S., & Avruch, J. (2007). The Rheb switch 2 segment is critical for signaling to TOR complex 1. Journal of Biological Chemistry, 282(25), 18542-18551.
19. Jefferies, H. B., Fumagalli, S., Dennis, P. B., Reinhard, C., Pearson, R. B., & Thomas, G. (1997). Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO Journal, 16, 3693-3704.
20. Stolovich, M., Tang, H., Hornstein, E., Levy, G., Cohen, R., Bae, S. S., et al. (2002). Transduction of growth or mitogenic signals into translational activation of TOP mRNAs is fully reliant on the phosphatidylinositol 3-kinase-mediated pathway but requires neither S6K1 nor rpS6 phosphorylation. Molecular and Cellular Biology, 22, 8101-8813.
21. Nourse, J., Firpo, E., Flanagan, W. M., Coats, S., Polyak, K., Lee, M. H., et al. (1994). Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature, 372, 570-573.
22. Kato, J. Y., Matsuoka, M., Polyak, K., Massague, J., & Sherr, C. J. (1994). Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell, 79, 487-496.
23. Chow, L. M., & Baker, S. J. (2006). PTEN function in normal and neoplastic growth. Cancer Letters, 241, 184-196.
24. Nakayama, K., Nakayama, N., Kurman, R. J., Cope, L., Pohl, G., Samuels, Y., et al. (2006). Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biology & Therapy, 5, 779-785.
25. Bertelsen, B. I., Steine, S. J., Sandvei, R., Molven, A., & Laerum, O. D. (2006). Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation. International Journal of Cancer, 118, 1877-1883.
26. Gao, X., Zhang, Y., Arrazola, P., Hino, O., Kobayashi, T., Yeung, R. S., et al. (2002). Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nature Cell Biology, 4, 699-704.
27. Astrinidis, A., & Henske, E. P. (2005). Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene, 24, 7475-7481.
28. Zacharek, S. J., Xiong, Y., & Shumway, S. D. (2005). Negative regulation of TSC1-TSC2 by mammalian D-type cyclins. Cancer Research, 65, 11354-11360.
29. Zhang, H., Cicchetti, G., Onda, H., Koon, H. B., Asrican, K., Bajraszewski, N., et al. (2003). Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. Journal of Clinical Investigation, 112, 1223-1233.
30. Inoki, K., Ouyang, H., Zhu, T., Lindvall, C., Wang, Y., Zhang, X., et al. (2006). TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell, 126, 955-968.
31. Feng, Z., Hu, W., de Stanchina, E., Teresky, A. K., Jin, S., Lowe, S., et al. (2007). The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Research, 67, 3043-3053.
32. Feng, Z., Zhang, H., Levine, A. J., & Jin, S. (2005). The coordinate regulation of the p53 and mTOR pathways in cells. Proceedings of the National Academy of Sciences of the United States of America, 102, 8204-8209.
33. Levine, A. J., Feng, Z., Mak, T. W., You, H., & Jin, S. (2006). Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes & Development, 20, 267-275.
34. Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., et al. (2004). The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell, 6, 91-99.
35. Mabuchi, S., Altomare, D. A., Connolly, D. C., Klein-Szanto, A., Litwin, S., Hoelzle, M. K., et al. (2007). RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Research, 67, 2408-2413.
36. Skeen, J. E., Bhaskar, P. T., Chen, C. C., Chen, W. S., Peng, X. D., Nogueira, V., et al. (2006). Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell, 10, 269-280.
37. Wu, Q., Kiguchi, K., Kawamoto, T., Ajiki, T., Traag, J., Carbajal, S., et al. (2007). Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. Cancer Research, 67, 3794-3800.
38. Namba, R., Young, L. J., Abbey, C. K., Kim, L., Damonte, P., Borowsky, A. D., et al. (2006). Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. Clinical Cancer Research, 12, 2613-2621.
39. Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., et al. (2004). mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nature Medicine, 10, 594-601.
40. Wimmer, C. D., Rentsch, M., Crispin, A., Illner, W. D., Arbogast, H., Graeb, C., et al. (2007). The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney International, 71, 1271-1278.
41. Sieghart, W., Fuereder, T., Schmid, K., Cejka, D., Werzowa, J., Wrba, F., et al. (2007). Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation, 83, 425-432.
42. Huang, S., Shu, L., Easton, J., Harwood, F. C., Germain, G. S., Ichijo, H., et al. (2004). Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity. Journal of Biological Chemistry, 279, 36490-36496.
43. Huang, S., Shu, L., Dilling, M. B., Easton, J., Harwood, F. C., Ichijo, H., et al. (2003). Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). Molecular Cell, 11, 1491-1501.
44. Hosoi, H., Dilling, M. B., Shikata, T., Liu, L. N., Shu, L., Ashmun, R. A., et al. (1999). Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Research, 59, 886-894.
45. Thimmaiah, K. N., Easton, J., Huang, S., Veverka, K. A., Germain, G. S., Harwood, F. C., et al. (2003). Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3′-kinase-Akt signaling pathways. Cancer Research, 63, 364-374.
46. Buck, E., Eyzaguirre, A., Brown, E., Petti, F., McCormack, S., Haley, J. D., et al. (2006). Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Molecular Cancer Therapeutics, 5, 2676-2684.
47. Raje, N., Kumar, S., Hideshima, T., Ishitsuka, K., Chauhan, D., Mitsiades, C., et al. (2004). Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood, 104, 4188-4193.
48. Beuvink, I., Boulay, A., Fumagalli, S., Zilbermann, F., Ruetz, S., O'Reilly T., et al. (2005). The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell, 120, 747-759.
49. Bruns, C. J., Koehl, G. E., Guba, M., Yezhelyev, M., Steinbauer, M., Seeliger, H., et al. (2004). Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clinical Cancer Research, 10, 2109-2119.
50. Seeliger, H., Guba, M., Koehl, G. E., Doenecke, A., Steinbauer, M., Bruns, C. J., et al. (2004). Blockage of 2-deoxy-d-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy. Clinical Cancer Research, 10, 1843-1852.
51. Cao, C., Subhawong, T., Albert, J. M., Kim, K. W., Geng, L., Sekhar, K. R., et al. (2006). Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Research, 66, 10040-10047.
52. Kim, K. W., Mutter, R. W., Cao, C., Albert, J. M., Freeman, M., Hallahan, D. E., et al. (2006). Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling. Journal of Biological Chemistry, 281, 36883-36890.
53. Paglin, S., Lee, N. Y., Nakar, C., Fitzgerald, M., Plotkin, J., Deuel, B., et al. (2005). Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells. Cancer Research, 65, 11061-11070.
54. Iwamaru, A., Kondo, Y., Iwado, E., Aoki, H., Fujiwara, K., Yokoyama, T., et al. (2007). Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene, 26, 1840-1851.
55. Zhang, D., Bar-Eli, M., Meloche, S., & Brodt, P. (2004). Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals. Journal of Biological Chemistry, 279, 19683-19690.
56. Zhang, D., & Brodt, P. (2003). Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene, 22, 974-982.
57. Hornberger, T. A., & Chien, S. (2006). Mechanical stimuli and nutrients regulate rapamycin-sensitive signaling through distinct mechanisms in skeletal muscle. Journal of Cellular Biochemistry, 97, 1207-1216.
58. Hornberger, T. A., Chu, W. K., Mak, Y. W., Hsiung, J. W., Huang, S. A., & Chien, S. (2006). The role of phospholipase D and phosphatidic acid in the mechanical activation of mTOR signaling in skeletal muscle. Proceedings of the National Academy of Sciences of the United States of America, 103, 4741-4746.
59. Hui, L., Rodrik, V., Pielak, R. M., Knirr, S., Zheng, Y., & Foster, D. A. (2005). mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells. Journal of Biological Chemistry, 280, 35829-35835.
60. Zheng, Y., Rodrik, V., Toschi, A., Shi, M., Hui, L., Shen, Y., et al. (2006). Phospholipase D couples survival and migration signals in stress response of human cancer cells. Journal of Biological Chemistry, 281, 15862-15868.
61. Meng, Q., Xia, C., Fang, J., Rojanasakul, Y., & Jiang, B. H. (2006). Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signalling, 18, 2262-2271.
62. Krishnamachary, B., Berg-Dixon, S., Kelly, B., Agani, F., Feldser, D., Ferreira, G., et al. (2003). Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Research, 63, 1138-1143.
63. Lang, S. A., Gaumann, A., Koehl, G. E., Seidel, U., Bataille, F., Klein, D., et al. (2007). Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. International Journal of Cancer, 120, 1803-1810.
64. Liu, L., Li, F., Cardelli, J. A., Martin, K. A., Blenis, J., & Huang, S. (2006). Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene, 25, 7029-7040.
65. Hudson, C. C., Liu, M., Chiang, G. G., Otterness, D. M., Loomis, D. C., Kaper, F., et al. (2002). Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Molecular and Cellular Biology, 22, 7004-7014.
66. Pugh, C. W., & Ratcliffe, P. J. (2003). Regulation of angiogenesis by hypoxia: role of the HIF system. Nature Medicine, 9. 677-684.
67. Zhong, H., Chiles, K., Feldser, D., Laughner, E., Hanrahan, C., Georgescu, M. M., et al. (2000). Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Research, 60, 1541-1545.
68. Huber, S., Bruns, C. J., Schmid, G., Hermann, P. C., Conrad, C., Niess, H., et al. (2007). Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney International, 71, 771-777.
69. Kobayashi, S., Kishimoto, T., Kamata, S., Otsuka, M., Miyazaki, M., & Ishikura, H. (2007). Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Science, 98, 726-733.
70. Baluk, P., Morikawa, S., Haskell, A., Mancuso, M., & McDonald, D. M. (2003). Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. American Journal of Pathology, 163, 1801-1815.
71. Carmeliet, P., & Jain, R. K. (2000). Angiogenesis in cancer and other diseases. Nature, 407, 249-257.
72. Morikawa, S., Baluk, P., Kaidoh, T., Haskell, A., Jain, R. K., & McDonald, D. M. (2002). Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. American Journal of Pathology, 160, 985-1000.
73. Folkman, J. (1971). Tumor angiogenesis: therapeutic implications. New England Journal of Medicine, 285, 1182-1186.
74. Ilan, N., Mahooti, S., & Madri, J. A. (1998). Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. Journal of Cell Science, 111(Pt 24), 3621-3631.
75. Yu, Y., & Sato, J. D. (1999). MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. Journal of Cellular Physiology, 178, 235-246.
76. Moon, S. O., Kim, W., Kim, D. H., Sung, M. J., Lee, S., Kang, K. P., et al. (2005). Angiopoietin-1 reduces iopromide-induced endothelial cell apoptosis through activation of phosphatidylinositol 3′-kinase/p70 S6 kinase. International Journal of Tissue Reactions, 27, 115-124.
77. Panka, D. J., & Mier, J. W. (2003). Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. Journal of Biological Chemistry, 278, 37632-37636.
78. Guba, M., Yezhelyev, M., Eichhorn, M. E., Schmid, G., Ischenko, I., Papyan, A., et al. (2005). Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood, 105, 4463-4469.
79. Steffel, J., Latini, R. A., Akhmedov, A., Zimmermann, D., Zimmerling, P., Luscher, T. F., et al. (2005). Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation, 112, 2002-2011.
80. Zhu, S., Viswambharan, H., Gajanayake, T., Ming, X. F., & Yang, Z. (2005). Sirolimus increases tissue factor expression but not activity in cultured human vascular smooth muscle cells. BMC Cardiovascular Disorders, 5, 22.
81. Butzal, M., Loges, S., Schweizer, M., Fischer, U., Gehling, U. M., Hossfeld, D. K., et al. (2004). Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Experimental Cell Research, 300, 65-71.
82. Chen, T. G., Chen, J. Z., & Wang, X. X. (2006). Effects of rapamycin on number activity and eNOS of endothelial progenitor cells from peripheral blood. Cell Proliferation, 39, 117-125.
83. Miriuka, S. G., Rao, V., Peterson, M., Tumiati, L., Delgado, D. H., Mohan, R., et al. (2006). mTOR inhibition induces endothelial progenitor cell death. American Journal of Transplantation, 6, 2069-2079.
84. Sodhi, A., Chaisuparat, R., Hu, J., Ramsdell, A. K., Manning, B. D., Sausville, E. A., et al. (2006). The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell, 10, 133-143.
85. Di Paolo, S., Teutonico, A., Leogrande, D., Capobianco, C., & Schena, P. F. (2006). Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: A crossroad between cancer and diabetes? Journal of the American Society of Nephrology, 17, 2236-2244.
86. Klos, K. S., Wyszomierski, S. L., Sun, M., Tan, M., Zhou, X., Li, P., et al. (2006). ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Research, 66, 2028-2037.
87. Zhou, X., Tan, M., Stone Hawthorne, V., Klos, K. S., Lan, K. H., Yang, Y., et al. (2004), Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clinical Cancer Research, 10, 6779-6788.
88. Pantuck, A. J., Seligson, D. B., Klatte, T., Yu, H., Leppert, J. T., Moore, L., et al. (2007). Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer, 109(11), 2257-2267.
89. Burczynski, M. E., Twine, N. C., Dukart, G., Marshall, B., Hidalgo, M., Stadler, W. M., et al. (2005). Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clinical Cancer Research, 11, 1181-1189.
90. Hidalgo, M., Buckner, J. C., Erlichman, C., Pollack, M. S., Boni, J. P., Dukart, G., et al. (2006). A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clinical Cancer Research, 12, 5755-5763.
91. Raymond, E., Alexandre, J., Faivre, S., Vera, K., Materman, E., Boni, J., et al. (2004). Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. Journal of Clinical Oncology, 22, 2336-2347.
92. Doherty, L., Gigas, D. C., Kesari, S., Drappatz, J., Kim, R., Zimmerman, J., et al. (2006). Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology, 67, 156-158.
93. Reardon, D. A., Quinn, J. A., Vredenburgh, J. J., Gururangan, S., Friedman, A. H., Desjardins, A., et al. (2006). Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clinical Cancer Research, 12, 860-868.
94. Goudar, R. K., Shi, Q., Hjelmeland, M. D., Keir, S. T., McLendon, R. E., Wikstrand, C. J., et al. (2005). Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Molecular Cancer Therapeutics, 4, 101-112.
95. Punt, C. J., Boni, J., Bruntsch, U., Peters, M., & Thielert, C. (2003). Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Annals of Oncology, 14, 931-937.
96. Atkins, M. B., Hidalgo, M., Stadler, W. M., Logan, T. F., Dutcher, J. P., Hudes, G. R., et al. (2004). Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. Journal of Clinical Oncology, 22, 909-918.
97. Chang, S. M., Wen, P., Cloughesy, T., Greenberg, H., Schiff, D., Conrad, C., et al. (2005). Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Investigational New Drugs, 23, 357-361.
98. Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K., Boni, J., et al. (2005). Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. Journal of Clinical Oncology, 23, 5294-5304.
99. Chan, S., Scheulen, M. E., Johnston, S., Mross, K., Cardoso, F., Dittrich, C., et al. (2005). Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. Journal of Clinical Oncology, 23, 5314-5322.
100. Duran, I., Kortmansky, J., Singh, D., Hirte, H., Kocha, W., Goss, G., et al. (2006). A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. British Journal of Cancer, 95, 1148-1154.
101. Margolin, K., Longmate, J., Baratta, T., Synold, T., Christensen, S., Weber, J., et al. (2005). CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer, 104, 1045-1048.
102. Andrassy, J., Graeb, C., Rentsch, M., Jauch, K. W., & Guba, M. (2005). mTOR inhibition and its effect on cancer in transplantation. Transplantation, 80, S171-S174.
103. Dudkin, L., Dilling, M. B., Cheshire, P. J., Harwood, F. C., Hollingshead, M., Arbuck, S. G., et al. (2001). Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clinical Cancer Research, 7, 1758-1764.
104. Peralba, J. M., DeGraffenried, L., Friedrichs, W., Fulcher, L., Grunwald, V., Weiss, G., et al. (2003). Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clinical Cancer Research, 9, 2887-2892.
105. Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., et al. (2004). Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Medicine, 10, 145-147.
106. Willett, C. G., Boucher, Y., Duda, D. G., di Tomaso, E., Munn, L. L., Tong, R. T., et al. (2005). Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. Journal of Clinical Oncology, 23, 8136-8139.
107. Hidalgo, M. (2004). New target, new drug, old paradigm. Journal of Clinical Oncology, 22, 2270-2272.
108. Wan, X., Shen, N., Mendoza, A., Khanna, C., & Helman, L. J. (2006). CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia, 8, 394-401